Issued 2026-08-13 at $2.90 · now $2.98 (2026-08-13, +2.8% since)
Based on its own history, a month from the 2026-08-13 close, PEPG has typically landed between $1.53 and $4.67 — a range of −47.2% to +60.9% from the issuance price $2.90.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,047 overlapping 1 month windows · 2022-05-06 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($2.90) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where PEPG has typically landed a month from the 2026-08-13 close of $2.9 — the range is history, not a prediction.
- now $2.98 (+2.8%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.87 (-1.1%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.38–$3.36
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.53–$4.67
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2026-03-04 | −74.4% | −74.4% | +0.0% |
| 2026-03-11 | −73.9% | −74.4% | +0.0% |
| 2026-03-10 | −73.9% | −73.9% | +2.1% |
| 3 best | |||
| 2025-09-03 | +331.1% | +0.0% | +331.1% |
| 2025-09-02 | +323.3% | −0.8% | +323.3% |
| 2025-08-29 | +306.0% | +0.0% | +337.1% |
1,047 overlapping windows · 2022-05-06 – 2026-08-13 · not cherry-picked
Pending catalysts
- March 2027 — Trial primary completion: Phase 2 primary completion: A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (source, as of 2026-08-14)
- January 2029 — Trial primary completion: Phase 2 primary completion: An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~5 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.